Aspire Biopharma authorizes USD 10 million share buyback program - ASBP News | RalliesAspire Biopharma authorizes USD 10 million share buyback program
A
ASBP• Board approves repurchase program
- Aspire Biopharma Holdings board authorized a USD 10 million common stock repurchase program, effective Sept. 9, 2026.
- Repurchases may be executed in open-market purchases or privately negotiated transactions, subject to market and regulatory conditions.
- Program has no expiration date; the board can suspend or terminate it at any time.
- Authorization cited roughly 1,500,000 common shares outstanding as of Sept. 8, 2026.
RGEN
•
